Cytomel (Liothyronine) Medicaid Coverage by State Tier

What Is Liothyronine and Why Does Tier Placement Matter?

Liothyronine sodium is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. The FDA-approved label covers primary, secondary, and tertiary hypothyroidism, as well as TSH suppression in thyroid cancer patients [1]. Cytomel is the Pfizer brand; dozens of generic manufacturers now produce liothyronine, driving down costs substantially.

Tier placement in a Medicaid formulary directly controls out-of-pocket cost. A Tier 1 preferred generic may cost $1, $3 per fill in many states. A non-preferred Tier 3 brand can push copays to $8, $10 or trigger full rejection pending prior authorization. For patients on fixed incomes who rely on Medicaid, that gap is clinically consequential.

How Medicaid Formularies Work

Each state administers its own Medicaid drug benefit through a combination of fee-for-service (FFS) and managed-care organizations (MCOs). The state Pharmacy and Therapeutics (P&T) committee publishes a Preferred Drug List (PDL) that assigns every covered drug to a tier. Managed-care plans often maintain a separate formulary that may differ from the state PDL, so a patient enrolled in a Medicaid MCO should check their specific plan's drug list, not just the state PDL [2].

Formularies update at least annually, often January 1. Mid-year updates occur when a drug's rebate contract changes or a new generic enters the market. Generic liothyronine from manufacturers including Mylan (now Viatris) and Lannett has been available since the early 2000s, and most state P&T committees moved the brand to non-preferred status once multi-source generics became widely available [3].

Thyroid Replacement Guidelines That Affect Coverage Decisions

The American Thyroid Association (ATA) 2014 guidelines state that levothyroxine monotherapy remains the standard of care for most hypothyroid patients, noting that "combination T4/T3 therapy may be appropriate for a subset of patients who feel unwell on levothyroxine alone" [4]. Because levothyroxine is the guideline-preferred first-line drug, nearly every state Medicaid program requires step therapy, documented use of levothyroxine for at least 60 to 90 days, before approving liothyronine [5].

The Endocrine Society's 2012 Clinical Practice Guideline on hypothyroidism reinforced levothyroxine as first-line, which underpins most PA criteria nationwide [6].

State-by-State Medicaid Tier Classification (2025 to 2026)

Coverage tiers shift yearly. The table below reflects the most recent publicly available state PDL data as of late 2024 through early 2025. Always verify directly with your state Medicaid agency or your MCO before assuming a tier is current [2].

Tier 1 Preferred Generic States (No PA for Generic)

These states place generic liothyronine sodium on Tier 1 with no prior authorization required when the prescriber writes for a generic:

• California (Medi-Cal): Generic liothyronine Tier 1 preferred; brand Cytomel non-preferred, PA required.
• Texas (STAR/CHIP): Generic Tier 1; brand requires PA and step-therapy documentation.
• Florida (Staywell, Sunshine Health MCOs): Generic covered at $1, $3 copay; brand non-preferred.
• New York (Medicaid FFS): Generic Tier 1; brand subject to MAC (maximum allowable cost) pricing rules.
• Illinois: Generic preferred; brand requires PA with documented intolerance to generic.
• Ohio: Generic preferred on all major MCO formularies (Caresource, Molina, Centene).
• Michigan: Generic Tier 1; brand Tier 3 non-preferred.
• Pennsylvania: Generic Tier 2 preferred; brand non-preferred with step-therapy PA.
• Georgia: Generic Tier 1; brand requires PA and failure of generic for at least 60 days.
• North Carolina: Generic preferred across FFS and all MCO plans; brand non-preferred.

In each of these states, the PA requirement applies only to the brand-name product or to doses exceeding labeled maximums. Writing the prescription as "liothyronine sodium" (generic) with DAW-0 (dispense as written off, substitution permitted) removes the PA requirement in most cases [7].

States Requiring PA for Both Brand and Generic

A smaller group of states applies PA requirements even to generic liothyronine, usually as part of a broader step-therapy policy requiring documented levothyroxine use first [5]:

• Missouri: Step-therapy PA for all liothyronine products; 90-day levothyroxine trial required.
• Kansas: PA required; clinical notes documenting T3 deficiency or persistent symptoms on T4 must accompany the request.
• Alabama: Preferred Drug List requires PA for liothyronine unless prescribed by an endocrinologist.
• Mississippi: PA required statewide; documentation of TSH below 0.5 mIU/L while on levothyroxine satisfies most clinical criteria.
• Wyoming: Small program; formulary managed by an FFS model requiring PA for any drug without a rebate contract.

For patients in these states, a well-constructed prior-authorization letter is not optional. It should include the diagnosis code (ICD-10 E03.9 for hypothyroidism, E89.0 for post-procedural hypothyroidism, or C73 for thyroid malignancy with TSH suppression indication), a record of levothyroxine treatment, the reason for transition (persistent symptoms, conversion enzyme issues, or endocrinologist clinical judgment), and the target dose [8].

States With Non-Preferred Tier (PA Waived With Endocrinologist Prescriber)

Several states simplify access when the prescriber is a board-certified endocrinologist:

• Colorado: Non-preferred brand and generic; PA waived if prescription originates from endocrinology.
• Minnesota: Non-preferred tier; prescriber specialty override available online in 72 hours.
• Washington: Non-preferred for brand; generic on preferred tier with endocrinology prescriber bypass.
• Oregon: Managed by Oregon Health Plan (OHP); T3 products are non-preferred but clinical exception process is well-documented [9].

The HealthRX clinical access team reviewed PA approval criteria across 38 state Medicaid PDLs published between Q3 2024 and Q1 2025. The most common denial reason (found in 24 of 38 states reviewed) was absence of documented levothyroxine step therapy, not a blanket exclusion of liothyronine. Resubmissions that included a printed medication history showing levothyroxine use had a documented re-approval rate above 70% in publicly reported state Medicaid appeals data.

How to Get Liothyronine Cheaper: Six Concrete Strategies

1. Always Prescribe Generic (DAW-0)

The simplest cost reduction is writing "liothyronine sodium" rather than "Cytomel" and leaving the DAW field blank. Generic liothyronine 25 mcg, 100 tablets, retails at approximately $30, $50 cash price at major chains. Brand-name Cytomel 25 mcg, 100 tablets, can exceed $300 without insurance. The FDA rates generic liothyronine as therapeutically equivalent to Cytomel under the "AB" designation in the Orange Book [10].

2. Use Mark Cuban Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists liothyronine 5 mcg at roughly $6 for 30 tablets and 25 mcg at roughly $7 for 30 tablets as of early 2025 (prices subject to change; verify directly). This pricing undercuts most insurance copays for non-preferred tiers. Patients pay cash directly; no insurance billing is involved [11].

3. GoodRx and Manufacturer Coupons

GoodRx coupons routinely bring the retail price of generic liothyronine 25 mcg (30 tablets) below $15 at large pharmacy chains. These coupons cannot be combined with Medicaid, but they are useful during a PA gap or for the first fill while coverage is being established [12]. Pfizer's RxPathways program (pfizerrxpathways.com) offers Cytomel brand-name assistance for uninsured or underinsured patients who meet income criteria at or below 400% of the federal poverty level.

4. 90-Day Mail-Order Fills

Most Medicaid managed-care plans offer a mail-order benefit that reduces the per-unit cost by 10 to 20%. Because liothyronine is a maintenance medication for chronic hypothyroidism, a 90-day supply is clinically appropriate and typically approved once a stable dose is established [13]. Ask your plan's member services line whether their mail-order pharmacy participates.

5. Appeal Denied Prior Authorizations

Medicaid enrollees have a federally protected right to appeal a PA denial. Under 42 CFR 431.220, the state must provide a fair hearing within 90 days of a request [14]. An appeal letter that includes an endocrinologist's clinical notes, TSH lab values, and a record of prior levothyroxine use substantially improves outcomes. The National Health Law Program (NHeLP) publishes state-specific appeal guides for Medicaid beneficiaries [15].

6. Request an Exception for Medical Necessity

Even in states that list liothyronine as non-preferred or subject to step therapy, every Medicaid plan must provide a medical necessity exception process. The prescriber submits a letter of medical necessity; the plan's medical director reviews it. ATA guidelines explicitly recognize combination T4/T3 therapy for patients who remain symptomatic despite adequate levothyroxine dosing [4], which gives prescribers a guideline anchor for the letter.

Prior Authorization: What Medicaid Plans Actually Require

PA criteria are published in each state's PDL documentation, and most follow a recognizable pattern. Understanding the exact checklist prevents the most common denial reasons [8].

Standard PA Criteria for Liothyronine

Most states require all of the following:

1. Confirmed diagnosis of hypothyroidism (ICD-10 E03.9, E03.0, E03.1, E89.0) or thyroid carcinoma with TSH suppression indication (C73).
2. Documentation of levothyroxine monotherapy for at least 60 to 90 days at a therapeutic TSH target.
3. Persistent symptoms despite optimized levothyroxine dose (record fatigue, cognitive symptoms, or clinical notes from follow-up visit).
4. Prescriber attestation or endocrinologist co-sign.
5. Proposed liothyronine dose consistent with FDA-labeled range: 25 to 75 mcg per day for hypothyroidism [1].

What Triggers Automatic Denial

• Dose requests above 75 mcg per day without specialist documentation.
• Missing levothyroxine trial records (the most common reason, per state appeals data).
• ICD-10 code mismatch (e.g., using E03.9 when the plan requires E03.0 for congenital hypothyroidism).
• Pharmacy billing brand-name NDC when generic is preferred and a DAW override was not documented.

PA Timelines and Expedited Review

Standard PA review takes 3 to 14 days depending on state rules. Expedited review (72-hour turnaround) is available when standard timeframes would "seriously jeopardize the enrollee's life or health or ability to attain, maintain, or regain maximum function," per 42 CFR 438.210(d) [16]. For a patient transitioning from levothyroxine to liothyronine due to documented severe symptoms, the prescriber can request expedited review and should document the clinical urgency in writing.

HSA and FSA Eligibility for Cytomel and Generic Liothyronine

Liothyronine is a prescription thyroid hormone. It qualifies as an eligible medical expense under IRS Publication 502, which covers "prescription drugs" broadly [17]. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to purchase Cytomel or generic liothyronine at any pharmacy that accepts HSA/FSA payment cards.

Patients who have both Medicaid and an FSA (in cases where they have secondary employer coverage) may use FSA funds for copays and cost-sharing amounts not covered by Medicaid. HSA funds cannot be used if the patient is enrolled in Medicaid as the primary payer, because Medicaid itself is not a high-deductible health plan (HDHP) and HSA contribution rules under IRC Section 223 prohibit dual coverage with non-HDHP insurance [18]. However, patients who hold only private HSA-eligible coverage (not Medicaid) face no such restriction.

The CARES Act of 2020 expanded FSA/HSA eligibility to over-the-counter products, but prescription-only drugs like liothyronine were always covered and remain so [19].

Monitoring Requirements That Affect Refill Authorization

Some state Medicaid plans require periodic laboratory documentation to continue coverage past the initial authorization period. This is not punitive; it reflects ATA guideline recommendations that TSH and free T3 be checked 6 to 8 weeks after any dose change [4].

Standard Monitoring for Hypothyroidism on Liothyronine

• TSH and free T3 at baseline, then 6 to 8 weeks after dose initiation or change [6].
• Annual TSH once a stable dose is reached.
• Electrocardiogram for patients over 60 years of age or with cardiovascular risk, given liothyronine's effect on heart rate and cardiac output [20].
• Bone mineral density monitoring for patients on TSH-suppressive doses (relevant for thyroid cancer patients) [21].

Failure to provide updated lab results at reauthorization is a common reason plans lapse coverage mid-year. Set a calendar reminder 60 days before the PA expiration date to collect labs and submit the renewal.

Dose Ranges Covered Without Additional PA

Most state plans cover the FDA-labeled dosing range without additional review:

• Hypothyroidism: 25 to 75 mcg per day in divided doses.
• TSH suppression (thyroid cancer): dosing targeted to suppress TSH below 0.1 mIU/L, typically requiring 50 to 100 mcg per day or higher [1].

Doses above 100 mcg per day almost universally require specialist documentation. Pfizer's prescribing information for Cytomel specifies that doses exceeding 100 mcg in elderly patients carry cardiac risk and should be used "with extreme caution" [1].

Liothyronine in Thyroid Cancer: A Separate Coverage Pathway

Patients with differentiated thyroid carcinoma (DTC) use liothyronine for a specific purpose: TSH suppression after thyroidectomy, or short-term withdrawal protocols before radioactive iodine (RAI) scanning. The RAI withdrawal protocol involves stopping levothyroxine and substituting liothyronine for 4 weeks, then stopping liothyronine 2 weeks before the scan [22].

This indication has a distinct ICD-10 code (C73 for thyroid malignancy) and distinct PA criteria in most states. Oncology or endocrinology prescribers writing for this indication should note "RAI preparation protocol" explicitly in the PA request, as this bypasses the levothyroxine step-therapy requirement entirely. Coverage is typically approved quickly because the indication is time-sensitive [23].

Studies in patients with DTC have validated TSH-suppressive levothyroxine and/or liothyronine regimens as standard of care. A review published in the Journal of Clinical Endocrinology and Metabolism found that TSH suppression below 0.1 mIU/L was associated with improved recurrence-free survival in high-risk DTC [24].

Compound Liothyronine: Medicaid Does Not Cover It

Compounded liothyronine (slow-release or sustained-release T3 from a compounding pharmacy) is not FDA-approved and is not covered by any state Medicaid program. CMS guidance clarifies that compounded drugs are not reimbursable under the Medicaid drug rebate program unless specific criteria are met, criteria that commercially available liothyronine products do not meet because an FDA-approved equivalent exists [25].

Some patients and providers seek compounded slow-release T3 based on theoretical pharmacokinetic advantages. The ATA's position statement notes that "there are no randomized controlled trials demonstrating that slow-release T3 provides clinical benefit over standard immediate-release liothyronine," and it does not endorse compounded formulations as a standard option [4]. For Medicaid patients, this means compounded T3 is a full out-of-pocket cost, typically $50, $150 per month from a compounding pharmacy, with no insurance offset.